Kyverna sets IPO range, eyeing $180M haul to fund broad autoimmune CAR-T clinical trial program ntaylor Thu, 02/01/2024 - 09:26.: Kyverna Therapeutics has laid the foundations for the next major IPO of 2024. Having filed last month, the autoimmune cell therapy biotech set the terms for an offering that could gross around $180 million on Thursday. California-based Kyverna previously received investment from Vida Ventures, the VC group set up by Kite Pharma founder Arie Belldegrun, M.D., and Gilead Sciences on the path to its IPO filing.